Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
Pfizer falls on weaker than expected 2024 revenue forecast
07:21am, Wednesday, 13'th Dec 2023
Pfizer shares have fallen 6.8% in pre-market trading after it forecast revenue and earnings below analyst expectations. The pharmaceutical giant said sales will reach $58.5 billion to $61.5 billion
Pfizer Stock Dives. Its New Guidance Is Disappointing the Market.
07:08am, Wednesday, 13'th Dec 2023
The pharmaceutical company said it expects adjusted earnings per share in the range of $2.05 to $2.25 for 2024. Wall Street was looking for $3.16.
Pfizer's stock down 7% as 2024 guidance for profit and revenue lags consensus
07:05am, Wednesday, 13'th Dec 2023
Pfizer Inc.'s stock PFE, -0.21% slid 7% premarket Wednesday, after the drug company set guidance for 2024 that lagged consensus. Pfizer, which is hosting an investor day later Wednesday, is expecting
Final Trades: Shake Shack, Pfizer, Humana and iShares US Healthcare
04:24pm, Tuesday, 12'th Dec 2023
The 'Halftime Report' traders give their top picks to watch for.
Call Traders Blast Pfizer Stock After Takeover Update
11:59am, Tuesday, 12'th Dec 2023
Bullish options traders are having a field day with Pfizer Inc. (NYSE:PFE), after the pharma company received all the regulatory approvals necessary to finalize its $43 billion acquisition of Seagen
AbbVie Just Followed Pfizer's Big Move. Here's What It Means For Investors
10:15am, Tuesday, 12'th Dec 2023
AbbVie is buying ImmunoGen to pocket its antibody drug conjugate (ADC) assets. Pfizer just did the same thing with Seagen on a much larger scale.
Pfizer to close Seagen acquisition after donating cancer drug rights
09:51am, Tuesday, 12'th Dec 2023
Pfizer Inc (NYSE:PFE) announced on Tuesday that it will donate the rights of royalties from sales of cancer drug Bavencio to the American Association for Cancer Research (AACR) in order to address con
Pfizer gets OK for $43-billion Seagen deal after donating cancer drug rights
07:06am, Tuesday, 12'th Dec 2023
Pfizer said on Tuesday it has agreed to donate the rights of royalties from sales of cancer drug Bavencio to address concerns from U.S. antitrust regulators related to its $43-billion deal to buy Seag
Pfizer's (PFE) Multiple Myeloma Drug Elrexfio Gets Nod in EU
01:32pm, Monday, 11'th Dec 2023
Pfizer's (PFE) targeted immunotherapy, Elrexfio, for treating heavily pretreated adults with relapsed/refractory multiple myeloma gets EC's conditional marketing authorization.
6 Health Care Dividend Stocks To By Hand Over Fist
10:48am, Monday, 11'th Dec 2023
This biotech giant remains a top stock for investors to buy and pays a solid 3.13% dividend.
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
10:32am, Monday, 11'th Dec 2023
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Is Pfizer Stock a Buy Now?
07:15am, Saturday, 09'th Dec 2023
Pfizer is discontinuing its twice-daily weight-loss drug, as the side effects proved to be problematic for patients. The company isn't giving up on developing a weight-loss drug, however; it's still m
3 Blue-Chip Stocks Set to Make a Comeback in 2024
09:00pm, Friday, 08'th Dec 2023
Investors look at blue-chip stocks for dividends and capital preservation. However, dividend stocks do not always trend higher.
Pfizer's Latest Ozempic Competitor Just Flopped (Again). Is the Stock Still a Buy?
09:30am, Friday, 08'th Dec 2023
Pfizer's latest play to make a competitor to Novo Nordisk's Ozempic has failed. This is the second failed attempt, and it might not be the last one.
7 Tech Stocks to Light Up Your Portfolio This Holiday Season
07:30am, Friday, 08'th Dec 2023
As the festive season rolls in, finding the best tech stocks to buy is exciting, lighting up various sectors with innovative energy. These industry giants are showing impressive resilience and growth
